[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Triple therapy with two antibiotics and acid-suppressing drugs is widely accepted for H. pylori eradication. Both H2-receptor antagonist and proton-pump inhibitor are reported to enhance the eradication rate when antibiotics are administered together. Comparative studies using H2-receptor antagonist or proton-pump inhibitor in triple therapy were reviewed. The efficacy of H. pylori eradication regimens with H2-receptor antagonist or proton-pump inhibitor with two antibiotics is not significantly different.
Kanayama
S
S
Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D015738:Famotidine / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D054328:Proton Pump Inhibitors; D011899:Ranitidine / Q000008:administration & dosage
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D015738:Famotidine; D011899:Ranitidine; D009853:Omeprazole